Research and Markets: Cancer Biologics Pipeline: Antibodies, Peptides, and Proteins - A Competitive Review - 2011

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/cde6bc/cancer_biologics_p) has announced the addition of Decision Resources, Inc.'s new report "Cancer Biologics Pipeline: Antibodies, Peptides, and Proteins - A Competitive Review" to their offering.

The cancer biologics pipeline - consisting of antibodies, peptides, and proteins - is robust (vetted to 162 verified agents from an initial list of 639), a notable finding given the high cost of developing these drugs and the pricing and reimbursement hurdles they will face post-approval. However, high unmet needs in many cancer indications and the low risk of biosimilar competition - relative to the risk of generic competition in therapeutic areas dominated by small-molecule drugs - make the cancer biologics market potentially lucrative for drug developers that can bear the development costs.

Questions Answered in This Report:

  • Agents in the cancer biologics pipeline aim for a wide array of drug targets. Why are the agents' targets so diverse? What are the most common drug targets?
  • The cancer biologics pipeline also focuses on a wide range of cancer indications. Why is the list of cancers targeted so wide ranging? What are the most commonly targeted cancers?
  • Despite the success of multiple cancer biologics on the market today, significant unmet needs remain for many cancer indications. What cancer indications could benefit most from newer cancer biologics? What unmet needs are most striking in these cancer indications?
  • Bristol-Myers Squibb's healthy pipeline of cancer biologics yielded a success in March 2011 as the FDA approved Yervoy (ipilimumab) for melanoma. How will BMS's standing among top cancer biologics marketers change by 2017? What other companies are vying for leadership in this sector?

Scope of the Report:

  • The cancer biologics pipeline: Number of agents in development; disease focus; NMEs versus reformulations; drug targets; solid-tumor drugs versus drugs for hematological malignancies; phase analysis; development by company type; number of agents by phase; number of agents by disease; profiles of Roche, Bristol-Myers Squibb, and Eli Lilly.
  • Historical and projected cancer biologic drug sales: 2006-2017 sales; leading drug classes; current and projected market-leading companies.
  • Markets covered: United States; rest of world.
  • Market opportunities: Targeted patient populations within cancer indications.
  • Market constraints: Development expenses; emerging biosimilar threat; pricing and reimbursement restrictions.
  • Data-rich content: 24 tables and figures that detail our pipeline and market findings

Companies Mentioned:

  • Abbott Laboratories
  • Amgen
  • Astellas Pharma
  • AstraZeneca
  • Bristol-Myers Squibb
  • Chugai
  • Eisai
  • Eli Lilly
  • ImmunoGen
  • Immunomedics
  • Kyowa Hakko Kirin
  • Merck KGaA
  • Micromet
  • MorphoSys
  • Novartis
  • Pfizer
  • Philogen
  • Roche
  • Sanofi-Aventis
  • Seattle Genetics
  • Takeda

For more information visit http://www.researchandmarkets.com/research/cde6bc/cancer_biologics_p



CONTACT:

Research and Markets
Laura Wood, Senior Manager,
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:

INDUSTRY KEYWORDS:   Health  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Seattle Genetics and Astellas’ newcomer Padcev now has what every cancer drugmaker is looking for: Randomized trial data showing it can extend lives.

A patent decision in Delaware clears the way for multiple generic companies to launch their Tecfidera copycats—and target its $3.3B in U.S. sales.

Sanofi and GlaxoSmithKline signed a deal with the EU to supply up to 300 million doses of their recombinant protein-based COVID-19 vaccine.